<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03232632</url>
  </required_header>
  <id_info>
    <org_study_id>13 199 02</org_study_id>
    <nct_id>NCT03232632</nct_id>
  </id_info>
  <brief_title>Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.</brief_title>
  <acronym>AMYLCAR</acronym>
  <official_title>Assessment of Cardiac Fixation During Positron Emission Tomography (PET) Examination Using 18F-Flutemetamol (Vizamyl ®) Within Amyloid Cardiac Injuries.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To estimate distribution's parameters of 18F-Flutemetamol (Vizamyl®) fixation on myocardium&#xD;
      for patients with amyloid cardiac injuries.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis had been performed that PET with 18F-Flutemetamol (Vizamyl®) could lead an early&#xD;
      diagnostic. Indeed, this tracer had been recently used to highlight inter-cerebral&#xD;
      beta-amyloid plaques on patients with Alzheimer Disease.&#xD;
&#xD;
      Because this labelling is performed on amyloid deposits, this tracer would lead to view and&#xD;
      to quantify amyloid deposits within cardiac amyloid injuries.&#xD;
&#xD;
      Results of this PET will be combined with scan examinations for a better anatomic tracking.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    intervention programming&#xD;
  </why_stopped>
  <start_date type="Actual">March 15, 2017</start_date>
  <completion_date type="Actual">September 15, 2019</completion_date>
  <primary_completion_date type="Actual">September 15, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ratio Heart/ Upper Mediastinum</measure>
    <time_frame>average of last 15 minutes</time_frame>
    <description>peak of 18F-Flutemetamol capture</description>
  </primary_outcome>
  <primary_outcome>
    <measure>standardized uptake value (SUV) measures</measure>
    <time_frame>average of last 15 minutes</time_frame>
    <description>standardized uptake value (SUV) measures</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Cardiac Amyloidosis</condition>
  <arm_group>
    <arm_group_label>PET with 18 F-Flutemetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PET with 18 F-Flutemetamol (Vizamyl®) = product under Alzheimer's disease indication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PET with 18 F-Flutemetamol</intervention_name>
    <description>PET with 18 F-Flutemetamol (Vizamyl ®)</description>
    <arm_group_label>PET with 18 F-Flutemetamol</arm_group_label>
    <other_name>Vizamyl®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients followed for amyloidosis with proved cardiac injury or strongly suspected:&#xD;
&#xD;
               -  cardiac echography with typical signs of amyloid injury,&#xD;
&#xD;
               -  anatomical result confirming presence of amyloid deposits at cardiac or&#xD;
                  peripheral level&#xD;
&#xD;
          -  Signature of Informed Consent Form,&#xD;
&#xD;
          -  Affiliation to a social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who suffers from another pathology which could lead cardiac injury (coronary&#xD;
             disease, valvular disease, other pathology of deposit),&#xD;
&#xD;
          -  Pregnancy and lactating women,&#xD;
&#xD;
          -  Absence of effective contraception,&#xD;
&#xD;
          -  Irradiating examination performed within the last 12 months or scheduled within the&#xD;
             next 12 months,&#xD;
&#xD;
          -  Unable patient physically, mentally or legally to provide informed consent,&#xD;
&#xD;
          -  Patient under a system of legal protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric OUHAYOUN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 11, 2017</study_first_submitted>
  <study_first_submitted_qc>July 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2017</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flutemetamol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

